Ani pharmaceuticals announces buyout of royalty obligation for iluvien® and yutiq®

Baudette, minn., march 18, 2025 (globe newswire) -- ani pharmaceuticals, inc. (nasdaq: anip) (ani or the company) today announced that it has completed the buyout of its 3.125% perpetual royalty obligation to swk funding llc (swk) on worldwide net revenues of iluvien and yutiq for a one-time payment of $17.25 million. under the terms of the agreement, upon making the buyout payment, no further royalty is due to swk on net revenues beginning january 1, 2025, forward. ani funded the buyout with cash on hand.
ANIP Ratings Summary
ANIP Quant Ranking